Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
Open Access
- 21 July 2016
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 1991-1997
Abstract
Cancer specific targeting sparing normal tissues would significantly enhance cancer therapy outcomes and reduce cancer-related mortality. One approach is to target receptors and/or molecules that are specifically expressed on cancer cells. Peptides as cancer-specific targeting agents offer advantages such as ease of synthesis, low antigenicity and enhanced diffusion into tissues. Glucose regulated protein 78 (GRP78) is an endoplasmic reticulum stress chaperone that regulates the unfolded protein response and is over expressed in various cancers. In this study we evaluated GIRLRG peptide that specifically targets GRP78 for cancer specific binding (in vitro) and non-invasive tumor imaging (in vivo). Methods: GIRLRG peptide was modeled into the GRP78 ATPase domain using computational modeling. Surface Plasmon Resonance studies were performed to determine the affinity of GIRLRG peptide to GRP78 protein. GIRLRG was conjugated with PEG to prolong its circulation in mice. Tumor binding efficacy of PEG-GIRLRG peptide was evaluated in nude mice bearing heterotopic cervical (HT3), esophageal (OE33), pancreatic (BXPC3), lung (A549) and glioma (D54) tumors. NanoSPECT/CT imaging of the mice was performed 48 h and 72 h after injecting with 111Indium (111In) labeled PEG-GIRLRG or PEG-control peptide. Post-SPECT biodistribution studies were performed 96 h post-injection of the radiolabeled peptides. Results: Using molecular modeling and surface plasmon resonance, we identified that GIRLRG was binding with a KD of 2.16 X 10-3 M in the ATPase domain of GRP78. GIRLRG peptide specifically bound to cervical, lung, esophageal and glioma cells. SPECT imaging revealed that 111In-PEG-GIRLRG specifically bound to cervical, esophageal, pancreatic, lung and brain tumors. Post SPECT biodistribution data also validated the SPECT imaging results. Conclusion: GIRLRG peptide specifically binds to the ATPase domain of GRP78. Radiolabeled PEG-GIRLRG could be used to target various cancers. Further studies would be required to translate PEG-GIRLRG peptide into the clinic.Keywords
This publication has 36 references indexed in Scilit:
- A Peptidic Unconjugated GRP78/BiP Ligand Modulates the Unfolded Protein Response and Induces Prostate Cancer Cell DeathPLOS ONE, 2012
- Emerging role of radiolabeled nanoparticles as an effective diagnostic techniqueEJNMMI Research, 2012
- Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of CancerTheranostics, 2012
- Radiopeptide Imaging and Therapy in EuropeJournal of Nuclear Medicine, 2011
- Targeted Nanoparticles That Deliver a Sustained, Specific Release of Paclitaxel to Irradiated TumorsCancer Research, 2010
- Cell Surface Relocalization of the Endoplasmic Reticulum Chaperone and Unfolded Protein Response Regulator GRP78/BiPJournal of Biological Chemistry, 2010
- Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agentJournal of Cancer Research and Clinical Oncology, 2010
- Crystal Structures of the ATPase Domains of Four Human Hsp70 Isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and HSPA5/BiP/GRP78PLOS ONE, 2010
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- Mechanistic Studies of a Peptidic GRP78 Ligand for Cancer Cell-Specific Drug DeliveryMolecular Pharmaceutics, 2007